Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation-Reference-Cited by-同舟云学术

Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation

Published:2021-10-26 Issue:4 Volume:150 Page:626-635
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Huang Chi‐Hsien¹²,Ju Jia‐Shiuan¹²,Chiu Tzu‐Hsuan¹²,Huang Allen Chung‐Cheng¹²,Tung Pi‐Hung¹²,Wang Chin‐Chou³,Liu Chien‐Ying¹²,Chung Fu‐Tsai¹²,Fang Yueh‐Fu¹²,Guo Yi‐Ke⁴,Kuo Chih‐Hsi Scott¹²⁴^ORCID,Yang Cheng‐Ta¹²

Affiliation:

1. Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung Memorial Hospital Chang Gung University, College of Medicine Taoyuan Taiwan

2. Thoracic Oncology Unit Chang Gung Memorial Hospital Cancer Center Taoyuan Taiwan

3. Division of Pulmonary and Critical Care Medicine Kaohsiung Chang Gung Memorial Hospital Kaohsiung Taiwan

4. Data Science Institute, Department of Computing Imperial College London London UK

Funder

Chang Gung Medical Foundation

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33821

Reference43 articles.

1. Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs

2. Long term follow-up of EGFR mutated NSCLC cases

3. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

4. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

5. Afatinib: emerging next‐generation tyrosine kinase inhibitor for NSCLC;Nelson V;Onco Targets Ther,2013

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review;Advances in Therapy;2024-03-21

2. An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report;Journal of Medical Case Reports;2024-03-18

3. Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study;BMC Cancer;2024-01-12

4. Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients;Journal of Cancer Research and Practice;2024-01

5. Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC;Scientific Reports;2023-11-21